BioAge Labs Stock (NASDAQ:BIOA)

Revenue Ownership Financials Chart

Previous Close

$12.75

52W Range

$2.88 - $13.10

50D Avg

$7.80

200D Avg

$5.22

Market Cap

$461.45M

Avg Vol (3M)

$418.18K

Beta

1.76

Div Yield

BIOA Company Profile

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Sep 26, 2024

Website

BIOA Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Sep 25	Jun 25	Mar 25
Operating Segments	$2.05M	$2.41M	$1.45M

Fiscal year ends in Dec 24 | Currency in USD

BIOA Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-78.19M	$-48.40M	$-39.97M
Net Income	$-71.11M	$-63.85M	$-39.72M
EBITDA	$-78.19M	$-55.90M	$-39.35M
Basic EPS	$-6.63	$-8.55	$-5.32
Diluted EPS	$-6.63	$-8.55	$-5.32

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
EDIT	Editas Medicine, Inc.
ACB	Aurora Cannabis Inc.
OMI	Owens & Minor, Inc.
LFCR	Lifecore Biomedical, Inc.
ALLO	Allogene Therapeutics, Inc.
CGC	Canopy Growth Corporation
HUMA	Humacyte, Inc.
AVIR	Atea Pharmaceuticals, Inc.
CABA	Cabaletta Bio, Inc.
TKNO	Alpha Teknova, Inc.